Omnicell Com Stock Price, News & Analysis

Omnicell, Inc. (NASDAQ:OMCL) reported Q2 2022 GAAP revenues of $331 million, a 22% increase year-over-year, despite a modest impact from a ransomware incident. GAAP net income was $9 million or $0.20 per diluted share, down from $20 million or $0.43 a year ago. Non-GAAP revenues also rose to $332 million, with non-GAAP net income at $38 million or $0.84 per diluted share, compared to $44 million or $0.97 previously. The company reaffirmed its full-year guidance, expecting revenues between $1.385 billion and $1.410 billion.

Omnicell, Inc. (NASDAQ: OMCL) will announce its Q2 2022 financial results on August 4, 2022, after market hours. The company will conduct a conference call at 1:30 p.m. PT to discuss the results. Omnicell specializes in medication management and adherence solutions aimed at improving healthcare outcomes and reducing costs. As a pioneer in autonomous pharmacy technology, it enhances operational efficiency and patient safety across healthcare systems.

Omnicell reported Q1 2022 GAAP and non-GAAP revenues of $319 million, a 27% increase year-over-year. GAAP net income was $8 million ($0.17/share), down from $14 million ($0.30/share) in Q1 2021. Non-GAAP net income remained stable at $38 million ($0.83/share). The company launched the IVX Station, aimed at improving medication management through automation. For FY 2022, Omnicell anticipates revenues between $1.385 billion and $1.410 billion, with non-GAAP EPS projected between $3.85 and $4.05.

Omnicell, Inc. (NASDAQ:OMCL) will release its Q1 2022 financial results on April 28, 2022, after market close. The company will hold a conference call at 1:30 p.m. PT to discuss the results. Interested parties can join by calling (888) 550-5424 in the U.S. or (646) 960-0819 internationally, using Conference ID 5370673. The press release also highlights Omnicell's commitment to transforming pharmacy care through automation and technology to enhance operational efficiency and patient safety.

Omnicell, Inc. (NASDAQ: OMCL) has launched the IVX Station, an advanced IV compounding robot designed to improve efficiency and patient safety in pharmacy care. This technology enhances throughput speed threefold compared to existing solutions, addressing past reliability issues. Alongside this, the Winter 2022 Release introduces various improvements, including Omnicell One scorecards, a new refrigerated carousel for drug management, and upgraded XT Anesthesia Workstation features. These innovations aim to streamline pharmacy operations amidst regulatory complexities and rising healthcare costs.

Omnicell announced changes to its Board of Directors, revealing that Jim Judson and Bruce Smith will not seek reelection at the 2022 Annual Meeting, reducing the board size to nine members. Mary Garrett has been nominated to join the board, enhancing its expertise in digital transformation and healthcare technology. Garrett's impressive background includes a lengthy tenure at IBM and current board positions at other companies. Additionally, Dan Johnston will retire as Executive VP and Chief Legal Officer. These moves are part of Omnicell's strategy to strengthen leadership and improve healthcare solutions.

Omnicell, a leader in medication management, has entered a 10-year agreement with UMC Health System in Lubbock, Texas, to implement its cloud-based solutions for pharmacy automation and patient engagement. This partnership aims to enhance operational efficiency and patient safety through advanced pharmacy technology.

With UMC's significant demand increase and high uninsured rates in Texas, the solutions are expected to improve health outcomes in underserved communities.

Omnicell's Autonomous Pharmacy vision will drive performance and allow clinicians to focus more on patient care.

Omnicell, Inc. (NASDAQ:OMCL) reported a robust performance in 2021, achieving total revenues of $1.132 billion, a 27% increase from the previous year. Fourth quarter revenues reached $311 million, marking a 25% year-over-year growth. The company ended 2021 with a product backlog of $1.254 billion and completed acquisitions to expand its service offerings. For 2022, Omnicell expects revenues between $1.385 billion and $1.410 billion, with guidance aiming for non-GAAP earnings of $3.75 to $3.95 per share.

Omnicell, Inc. (NASDAQ:OMCL) will release its financial results for Q4 and full-year 2021 on February 14, 2022, after market close. A conference call and webcast to discuss these results will follow at 1:30 p.m. PT the same day. Interested parties can participate by calling (888) 550-5424 in the U.S. or (646) 960-0819 internationally. Omnicell focuses on improving pharmacy care delivery through automation and technology, with over 7,000 facilities utilizing its solutions globally.